Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times UK
International Business Times UK
World
Ria Pathak

TrumpRx News: Why Donald Trump Struck a Deal With Novo Nordisk's Weight Loss Drugs — And What It Says About America's Obesity Problem

US President Donald Trump speaks during a meeting at the White House (Credit: AFP News)

In one of the most sweeping health policy announcements of his second term, President Donald Trump has unveiled new agreements with pharmaceutical giants Novo Nordisk and Eli Lilly that significantly reduce the cost of blockbuster obesity drugs, including Wegovy, Ozempic, and Zepbound.

Under the deal, announced Thursday, certain GLP-1 weight loss medications will be available for as little as $149 (approximately £114) per month, a sharp drop from the current average retail price of $1,000–$1,350 (approximately £762-1,029). The discounts will be offered through the federal government's upcoming TrumpRx platform, which launches in early 2026, according to reports.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.